UK Dementia Research Institute
GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B
Over 240 million people worldwide live with chronic hepatitis B
GSK signs agreement with Protas to streamline clinical trials
The new three-year agreement builds on an existing two-year relationship
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
GSK’s Blenrep approved by FDA for multiple myeloma
Approval supported by positive results from phase 3 trial
Lilly and WHO Foundation partner to support global dementia action plan
The partnership will provide financial support and strengthen early detection and intervention efforts
Lilly launches global Alzheimer’s campaign with Julianne Moore
The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health
TRIMTECH Therapeutics establishes Scientific Advisory Board
Alessio Ciulli has been appointed as Chair of the board
GSK and Hengrui enter multi-programme collaboration agreement worth $12bn
The deal includes a PDE3/4 inhibitor in clinical development for COPD
Roche shares promising data from Alzheimer’s disease development portfolio
The company is planning to initiate phase 3 studies of trontinemab in early AD this year